Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

List of Essential Medicines Lebanon 2018


Foreword
 
Essential medicines as defined by the World Health Organization (WHO) are “those that satisfy the priority health care needs of the population. They are selected with due regard to public health relevance, evidence on efficacy and safety, and comparative cost-effectiveness. Essential medicines are intended to be available within the context of functioning health systems at all times in adequate amounts, in the appropriate dosage forms, with assured quality and adequate information, and at a price the individual and the community can afford. The implementation of the concept of essential medicines is intended to be flexible and adaptable to many different situations; exactly which medicines are regarded as essential remains a national responsibility”.
 
The WHO Model list of Essential Medicines revised every two years provides a template and serves as a guide for countries to prepare their own lists taking into consideration local priorities.

Based on the current version of the WHO Model List of Essential medicines 20th edition published in 2017, the Ministry of Public Health in Lebanon through the Quality Assurance of Pharmaceutical Products Program prepared the National List of Essential Medicines EML 2018, four years after the last edition in 2014. The EML 2018 contains around 350 medicinal products and was prepared over one year by a Committee of Experts.

The EML is aligned with the National Drug Formulary and National Health Programs such as EIP Mother & Child, TB Control, HIV/AIDS, Malaria, National Mental Health Program and Primary Healthcare. The formulation and strengths of medicines listed in the EML are those mentioned under these National Health Programs and National Drug Formulary.
 
The Lebanese EML 2018 contains a core list and complementary list:

The core list presents a list of minimum medicine needs for a basic health care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The complementary list presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.
 
The list is divided into 30 sections related to the main Therapeutic classes of medicines and arranged in three columns;
 
  1. INN of the medicine,
  2. Dosage form and strength of the medicine
  3. Official Status of the medicine 
 
Medicines and dosage forms are listed in alphabetical order within each section with no implication of preference for one form over another.
 
The following symbols are used in the list to indicate the status of the medicine:
 
R: Registered drug in the Ministry of Public Health
NR: Non Registered drug in the Ministry of Public Health
HIV: included in the HIV Program
M: included in the MALARIA Program
NMHP: included in the NATIONAL MENTAL HEALTH Program
TB: included in the TUBERCULOSIS Program
U: provided through UNICEF Program
Y: provided through YMCA Program
[a]: indicates that there is an age or weight restriction on use of the medicine.
 
An index listing the Medicines by alphabetical order is available at the end of the document facilitating retrieval of information and easy reference.
 
We hope that all health providers would embrace this document as important tool for management of medicines and rationalizing prescription in the country. The EML 2018 welcomes comments from healthcare professionals; such comments help us to ensure that the National Essential medicines list remains relevant to practice.
 
The list can be accessed from the official website of the Ministry of Public Health:  www.moph.gov.lb
 

List of Essential Medicines Lebanon 2018
    ...
    32
    ...
ATC Name B/G Ingredients Dosage Form Price
J01DD08 SUPRAX B Cefixime (trihydrate) - 400mg 400mg Capsule 2,053,391 L.L
L04AX02 THALIDOMIDE CELGENE B Thalidomide - 50mg 50mg Capsule 27,387,764 L.L
M03BX02 SIRDALUD B Tizanidine HCl - 2mg 2mg Tablet 631,148 L.L
R03DC03 SINGULAIR PAEDIATRIC B Montelukast (sodium) - 4mg 4mg Granules 1,248,430 L.L
S01FA06 MYDRIACYL B Tropicamide - 1% 1% Drops solution 430,030 L.L
A03BB01 BUSCOPAN B Butylscopolamine bromide - 10mg 10mg Tablet, sugar coated 291,614 L.L
B05AA06 GELASPAN B Gelatine, succinylated - 4% 4% Injectable solution 9,107,572 L.L
D01AC12 LOMEXIN B Fenticonazole nitrate - 2g/100g 2% Cream 729,154 L.L
G02AD02 PROPESS B Dinoprostone - 10mg 10mg Vaginal delivery system 5,838,996 L.L
J01DD08 SUPRAX B Cefixime (trihydrate) - 400mg 400mg Capsule 2,053,391 L.L
M03BX02 SIRDALUD B Tizanidine HCl - 4mg 4mg Tablet 826,175 L.L
N02CC01 IMIGRAN B Sumatriptan (succinate) - 50mg 50mg Tablet, film coated 378,964 L.L
B05AA07 VOLUVEN B Starch poly(O-2-Hydroxyethyl) - 6% 6% Injectable solution 987,724 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 25mg Tablet, film coated 900,374 L.L
D01AC14 DERMOFIX B Sertaconazole nitrate - 20mg/g 2% Cream 382,995 L.L
M03BX04 MYDOCALM B Tolperisone - 150mg 150mg Tablet, film coated 839,902 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet, film coated 306,396 L.L
B05BA01 AMINOVEN 10% B Glacial Acetic Acid 99% - 5.297g/l, L-Proline - 15.0g/l, L-Alanine - 15.0g/l, Glycine - 14.0g/l, L-Histidine - 3.00g/l, L-Arginine - 12.0g/l, L-Valine - 6.20g/l, L-Tryptophan - 2.00g/l, L-Threonine - 4.40g/l, L-Phenylalanine - 5.10g/l, L-Methionine - 4.30g/l, L-Lysine (monoacetate) - 6.60g/l, L-Leucine - 7.40g/l, L-Isoleucine - 5.00g/l Injectable solution 951,440 L.L
C07AG02 DILATREND B Carvedilol - 6.25mg 6.25mg Tablet, scored 364,181 L.L
D01AE14 MYCOSTER B Ciclopirox - 8g/100g 8% Film forming solution 756,583 L.L
L01BC08 DACOGEN B Decitabine - 50mg 50mg Injectable lyophilised powder for solution 87,048,758 L.L
N05AX08 RISPERDAL B Risperidone - 1mg 1mg Tablet, film coated 306,396 L.L
A10BA02 GLUCOPHAGE XR B Metformin HCl - 500mg 500mg Tablet, prolonged release 465,968 L.L
B05BA01 AMINOVEN INFANT B L-Leucine - 13g/l, L-Isoleucine - 8g/l, L-Lysine Acetate - 12g/l, L-Methionine - 3.12g/l, L-Phenylalanine - 3.75g/l, L-Threonine - 4.40g/l, L-Tryptophan - 2.01g/l, L-Valine - 9g/l, Arginine - 7.5g/l, L-Histidine - 4.76g/l, Glycine - 4.15g/l, L-Taurine - 0.40g/l, L-Serine - 7.67g/l, L-Alanine - 9.3g/l, L-Proline - 9.71g/l, N-Acetyl-L-Tyrosine - 5.176g/l, N-Acetyl-L-Cysteine - 0.70g/l, L-Malic Acid - 2.62g/l 10% Injectable solution 880,217 L.L
C09DA08 VOTUM PLUS B Olmesartan medoxomil - 20mg, Hydrochlorothiazide - 12.5mg Tablet, film coated 900,374 L.L
D01AE14 MYCOSTER B Ciclopirox - 8g/100g 8% Film forming solution 756,583 L.L
L01BC08 DACOGEN B Decitabine - 50mg 50mg Injectable lyophilised powder for solution 87,048,758 L.L
N06DX01 EBIXA B Memantine - 20mg 20mg Tablet, film coated 4,004,651 L.L
A16AB02 CEREZYME B Imiglucerase - 400IU 400IU Injectable lyophilised powder for solution 128,412,818 L.L
B05BA01 AMINOPLASMAL B. BRAUN B Amino acids - 10% 10% Injectable solution 1,036,103 L.L
    ...
    32
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025